GlobeNewswire: GlucoTrack, Inc. Contains the last 10 of 58 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T12:29:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/12/2844638/0/en/GLUCOTRACK-EXPANDS-LEADERSHIP-TEAM-WITH-NEW-VICE-PRESIDENT-OF-QUALITY.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY2024-03-12T13:30:00Z<![CDATA[Rutherford, NJ, March 12, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Vincent Wong has joined the Company as Vice President of Quality.]]>https://www.globenewswire.com/news-release/2024/02/27/2836038/0/en/GLUCOTRACK-SELECTS-CIRTEC-MEDICAL-AS-MANUFACTURER-FOR-ITS-IMPLANTABLE-CONTINUOUS-BLOOD-GLUCOSE-MONITOR.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR2024-02-27T13:30:00Z<![CDATA[Rutherford, NJ & Brooklyn Park, MN, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the selection of Cirtec Medical Corp, the leading medical device solutions provider of implantable therapies, as manufacturer for the implantable Continuous Blood Glucose Monitor (CBGM). The two companies have signed a development agreement for clinical and commercial manufacturing.]]>https://www.globenewswire.com/news-release/2024/02/13/2828367/0/en/GLUCOTRACK-ANNOUNCES-THE-APPOINTMENT-OF-LUIS-MALAV%C3%89-TO-CHAIR-OF-THE-BOARD-OF-DIRECTORS.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS2024-02-13T14:30:00Z<![CDATA[Rutherford, NJ, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes announced today that Luis Malavé has been elected as Chairman of its Board of Directors, effective immediately.]]>https://www.globenewswire.com/news-release/2024/01/02/2802856/0/en/GLUCOTRACK-ANNOUNCES-EARLY-ACCURACY-DATA-FOR-ITS-IMPLANTABLE-CONTINUOUS-GLUCOSE-MONITOR.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR2024-01-02T17:33:00Z<![CDATA[Rutherford, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, provides, updates on initial and long-term preclinical testing for the implantable Continuous Blood Glucose Monitor™ (CBGM).]]>https://www.globenewswire.com/news-release/2023/11/30/2789020/0/en/GLUCOTRACK-ANNOUNCES-180-DAY-EXTENSION-TO-REGAIN-COMPLIANCE-WITH-NASDAQ-MINIMUM-BID-PRICE-REQUIREMENT.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT2023-11-30T22:39:00Z<![CDATA[Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until May 20, 2024, to regain compliance with Nasdaq’s minimum bid price rule.]]>https://www.globenewswire.com/news-release/2023/11/13/2779119/0/en/GLUCOTRACK-ANNOUNCES-SHAREHOLDER-UPDATE.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE2023-11-13T14:00:00Z<![CDATA[Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.]]>https://www.globenewswire.com/news-release/2023/10/12/2759242/0/en/GLUCOTRACK-ANNOUNCES-PRECLINICAL-TESTING-WITH-IMPLANTABLE-CONTINUOUS-GLUCOSE-MONITOR.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR2023-10-12T12:30:00Z<![CDATA[Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing.]]>https://www.globenewswire.com/news-release/2023/08/31/2735263/0/en/GLUCOTRACK-ANNOUNCES-THE-APPOINTMENT-OF-ERIN-CARTER-TO-BOARD-OF-DIRECTORS.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS2023-08-31T12:30:00Z<![CDATA[Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately.]]>https://www.globenewswire.com/news-release/2023/08/28/2732624/0/en/GLUCOTRACK-ANNOUNCES-NEW-VP-OF-MARKETING.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES NEW VP OF MARKETING2023-08-28T13:00:00Z<![CDATA[Rutherford, NJ, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Drinda Benjamin has joined the company as Vice President of Marketing.]]>https://www.globenewswire.com/news-release/2023/07/25/2710472/0/en/GLUCOTRACK-ANNOUNCES-POSITIVE-DATA-FROM-FEASIBILITY-STUDY-FOR-IMPLANTABLE-CONTINUOUS-GLUCOSE-MONITOR.html?f=22&fvtc=4&fvtv=49477GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR2023-07-25T13:00:00Z<![CDATA[Rutherford, NJ, July 25, 2023 (GLOBE NEWSWIRE) -- - Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes.]]>